Status:
UNKNOWN
HA Residents With PVD, Pulmonary Artery Pressure (PAP) Assessed at HA (2840m) With and Without Supplemental Oxygen Therapy (SOT)
Lead Sponsor:
University of Zurich
Conditions:
Pulmonary Vascular Disorder
Pulmonary Artery Hypertension
Eligibility:
All Genders
18-80 years
Phase:
NA
Brief Summary
To study the effect of SOT in patients with pulmonary vascular diseases (PVD) defined as pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension (PH) who permanently live \>25...
Detailed Description
Patients with PVD diagnosed with precapillary PH with right heart catheterization and classified to groups 1 and 4 (PAH or CTEPH) who permanently live at HA \>2500 (PVDHA) will have echocardiografy to...
Eligibility Criteria
Inclusion
- Adult patients 18-80 years old of both genders,
- Residence \> 2500m of altitude
- diagnosed with precapillary PH (mean pulmonary artery pressure (mPAP) \>20 mmHg, pulmonary artery wedge pressure (PAWP) ≤15 mmHg and pulmonary vascular resistance (PVR) ≥2 wood units (WU) by right heart catheterization) with PH being classified as PAH or CTEPH according to guidelines
- Patients stable on therapy
- New York Heart Association (NYHA) functional class I-III
- Provided written informed consent to participate in the study.
Exclusion
- Age \<18 years or \>80 years
- unstable condition
- Patients who cannot follow the study investigations, patient permanently living \< 2500m.
- Patients with moderate to severe concomitant lung disease (FEV1\<70% or forced vital capacity \<70%), severe parenchymal lung disease, severe smokers (\>20 cigarettes/day)
- Severely hypoxemic patients at Quito permanently have persistent oxygen saturation by pulseoximetry (SpO2) \<80% on ambient air.
- Patients with chronic mountain sickness (Hemoglobin \> 19 g/dl in women, \>21 g/dl in men)
- Patient with a non-corrected ventricular septum defect
- Relevant concomitant other disease of the heart, kidney, liver, blood (anemia hemoglobin\<11 g/dl)
Key Trial Info
Start Date :
July 5 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2023
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT06084559
Start Date
July 5 2023
End Date
December 31 2023
Last Update
October 16 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital Zürich
Zurich, Switzerland, 8091